Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

What do you think about BMC? Take part in

Commentary/Editorials

Section edited by Christian Capitini, MD

Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.

Previous Page Page 1 of 2 Next Page
  1. Content type: Commentary

    Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent art...

    Authors: Marc-Elie Nader, Jeffrey N. Myers and Paul W. Gidley

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:24

    Published on:

  2. Content type: Commentary

    Inbred mice are the mainstay for preclinical cancer assessment of potential therapeutics, especially immune-based approaches. However, the use of young, lean, inbred mice housed under specific-pathogen-free co...

    Authors: William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:88

    Published on:

  3. Content type: Commentary

    The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of...

    Authors: Sonia T. Chelbi and Greta Guarda

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:39

    Published on:

  4. Content type: Commentary

    The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in compa...

    Authors: Mizuki Nishino

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:30

    Published on:

  5. Content type: Commentary

    Mounting an immune response sufficient to eradicate a tumor is the goal of modern immunotherapy. Single agent therapies with checkpoint inhibitors or costimulatory molecule agonists are effective only for a sm...

    Authors: Stefanie N. Linch and William L. Redmond

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:31

    Published on:

  6. Content type: Commentary

    The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule ...

    Authors: Howard L. Kaufman, Lisa H. Butterfield, Pierre G. Coulie, Sandra Demaria, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Ira Mellman, Pamela S. Ohashi, Willem W. Overwijk, Suzanne L. Topalian and Francesco M. Marincola

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:37

    Published on:

  7. Content type: Commentary

    Attention has recently focused on new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor responses. To this end, administration of antibodies that target inhibitory molecules regulati...

    Authors: Per thor Straten and Federico Garrido

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:23

    Published on:

  8. Content type: Commentary

    Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of solid–tissue cancers. Despite the recent advances there are still significant barriers, in particu...

    Authors: Steven K. Grossenbacher, Robert J. Canter and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:19

    Published on:

Previous Page Page 1 of 2 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement